Neuro News Roundup: Multiple Sclerosis
Risk factors regarding MS, including genetic research findings and progressive multifocal leukoencephalopathy while taking natalizumab, are discussed.
New recommendations aim to reduce the risk for progressive multifocal leukoencephalopathy (PML) with use of natalizumab in patients with relapsing remitting multiple sclerosis (RRMS). RRMS patients taking natalizumab who seroconvert to high levels of signaling antibodies are at increased risk of PML. In a new finding, seven loci have been added to the list of genuine MS genetic risk factors.
Neuro News Roundup: Multiple Sclerosis. March 2016
Those at High Risk of PML with Natalizumab. EMA link.
Those at High Risk of PML with Natalizumab.
Natalizumab Increases JC Virus Antibody Index in RRMS. article link.
Seven Novel MS Risk Loci. abstract link.
Take-home Messages
Latest News
The Wide-Reaching Impact of Multiple Sclerosis DMT Wastes: Darin T. Okuda, MD; Karin Cook
Pepinemab’s Upregulation of SEMA4D Expression Warrants Further Development in Huntington, Alzheimer Disease
Future Relapse Remission in Multiple Sclerosis Impacted by Retinal Layer Thinning
Using the Cognitive Stress Test to Distinguish Pre-MCI and Amnestic MCI: Leeron Nahmias, BS